Buerk Bjoern Thorben, Helke Charlotte, Richter Emilia, Menzel Viktoria, Borkowetz Angelika, Thomas Christian, Baunacke Martin
Department of Urology, University Rostock, 18057 Rostock, Germany.
Department of Urology, TU Dresden, 01307 Dresden, Germany.
Cancers (Basel). 2025 Feb 7;17(4):565. doi: 10.3390/cancers17040565.
BACKGROUND/OBJECTIVES: Patients with germ cell tumors have a good prognosis, which is partly due to platin-based chemotherapy. However, the long-term effects of CTx may play a relevant role in the long-term effects. Up to now, little is known about the knowledge that testicular tumor survivors have about these long-term effects.
A survey of testicular tumor patients treated at the University Hospital Dresden from 2011 up to 2021 was conducted. Patients who had received CTx were asked about their knowledge of the therapy and long-term effects.
Of the 279 returns (6 deceased, 46 unavailable, 64% response), 198 patients had received CTx. This was followed up by 63 different urologists. The follow-up period was 5.3 ± 2.9 years. A total of 5% (10/197) did not remember receiving CTx. A total of 55% (102/187) could not name the type of CTx. The most commonly known long-term effects were the risk of second tumors (63%) and andrological problems (59-60%). A total of 18.7% of patients did not know any long-term effects. Half of the patients (54.3%) knew a maximum of 5/14 long-term effects. In a multivariate analysis, a low educational degree (OR 2.2 (1.2-4.3); = 0.02) and one course of carboplatin (OR 3.1 (1.1-9.3); = 0.04) were the independent predictors for a knowledge deficit.
Germ cell tumor patients have a low level of awareness of the long-term effects of CTx. This results in a risk of inadequate prevention and follow-up, which, in turn, may have an impact on patients' long-term survival.
背景/目的：生殖细胞肿瘤患者预后良好，部分原因是基于铂类的化疗。然而，化疗的长期影响可能在远期效应中起相关作用。到目前为止，关于睾丸肿瘤幸存者对这些长期影响的了解知之甚少。
对2011年至2021年在德累斯顿大学医院接受治疗的睾丸肿瘤患者进行了一项调查。接受过化疗的患者被问及他们对治疗及其长期影响的了解情况。
在279份回复中（6人已故，46人无法联系，回复率64%），198名患者接受过化疗。随后由63位不同的泌尿科医生进行随访。随访期为5.3±2.9年。共有5%（10/197）的患者不记得接受过化疗。共有55%（102/187）的患者说不出化疗的类型。最常被知晓的长期影响是患第二种肿瘤的风险（63%）和男科问题（59 - 60%）。共有18.7%的患者不知道任何长期影响。一半的患者（54.3%）最多知道14种长期影响中的5种。在多变量分析中，低教育程度（比值比2.2（1.2 - 4.3）；P = 0.02）和一个疗程的卡铂治疗（比值比3.1（1.1 - 9.3）；P = 0.04）是知识欠缺的独立预测因素。
生殖细胞肿瘤患者对化疗长期影响的知晓程度较低。这导致预防和随访不足的风险，进而可能影响患者的长期生存。
